35 completed, 8 active not recruiting, 5 recruiting, 1 terminated. 22 Phase 3, 13 Phase 1, 7 Phase 2, 6 Phase 4.
By phase and status
Follow SKYRIZI: new trials by email Literature Review of SKYRIZI trials Research Report on SKYRIZI
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease Phase 2 Recruiting 80 2025-12-12 2026-07-09 Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants SKYRIZI, CKD-704 - Psoriasis Phase 1 Recruiting 213 2025-11-26 2025-12-19 A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants Risankizumab - Healthy Volunteers Phase 1 Completed 59 2025-05-08 2025-12-26 A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants Risankizumab - Healthy Volunteer Phase 1 Completed 263 2025-04-21 2025-11-17 A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants Risankizumab - Healthy Volunteers Phase 1 Completed 231 2024-09-11 2025-05-16 A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants Risankizumab - Healthy Volunteers Phase 1 Completed 60 2024-07-23 2025-02-18 A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab Adalimumab, Risankizumab - Juvenile Psoriatic Arthritis Phase 3 Recruiting 40 2024-07-08 2026-09-01 A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease Breast Milk Sampling, Risankizumab - Inflammatory Bowel Disease Phase 4 Completed 10 2024-04-24 2026-04-20 VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study Vedolizumab (VDZ), Ustekinumab (UST), Risankizumab (RISA) - Crohn's Disease Active not recruiting 300 2024-03-20 2026-11-02 A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease Risankizumab - Crohn's Disease Phase 3 Recruiting 110 2023-12-11 2026-10-20 A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. Risankizumab SC, Placebo for risankizumab - Crohn's Disease Phase 3 Active not recruiting 289 2023-11-15 2025-09-09 Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis Risankizumab, Placebo for Risankizumab - Genital Psoriasis, Scalp Psoriasis Phase 4 Completed 214 2023-08-10 2026-02-24 High Dose Risankizumab for Psoriasis risankizumab - Psoriasis Phase 2 Completed 20 2022-03-01 2025-10-24 A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis Guselkumab, Risankizumab - Arthritis, Psoriatic, Healthy Phase 1 Terminated 11 2021-11-04 2022-07-26 Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications Risankizumab, Comparator - Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment Recruiting 818 2021-07-30 2025-07-17 Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 Risankizumab - Psoriasis Phase 3 Active not recruiting 132 2021-07-24 2025-08-12 Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting Risankizumab, Comparator 1, Comparator 2 - Psoriasis Withdrawn 2021-06-23 2022-12-09 Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy Risankizumab, Apremilast - Psoriasis Phase 4 Completed 352 2021-06-09 2024-04-30 Risankizumab Long-term Remission Study Risankizumab-Rzaa, Punch biopsies of the skin at baseline visit, Punch biopsies of the skin at week 28 visit - Psoriasis Phase 4 Completed 24 2021-04-07 2026-05-27 Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement Placebo for Risankizumab, Risankizumab - Psoriasis Phase 3 Completed 174 2021-02-26 2024-06-14
Showing 20 of 51. Sign in to see all of them.
Conditions studied Psoriasis (20) · Crohn Disease (10) · Arthritis, Psoriatic (8) · Colitis, Ulcerative (3) · Skin Diseases (3) · Skin Diseases, Papulosquamous (3) · Arthritis, Juvenile (2) · Spondylitis, Ankylosing (2) · Arthritis, Rheumatoid (1) · Breast Feeding (1) · Dermatomyositis (1) · Giant Cell Arteritis (1) · Granulomatosis with Polyangiitis (1) · Hidradenitis Suppurativa (1) · Inflammatory Bowel Diseases (1)
Sponsors AbbVie (43) · Alimentiv Inc. (1) · Chong Kun Dang Pharmaceutical (1) · Istituto Clinico Humanitas (1) · Jaehwan Kim (1) · Janssen Research & Development, LLC (1) · NYU Langone Health (1) · Oregon Medical Research Center (1) · Radboud University Medical Center (1)
Countries United States (35) · Canada (18) · Germany (18) · Poland (16) · Spain (16) · United Kingdom (14) · Israel (13) · Italy (11) · Netherlands (11) · Australia (10) · Belgium (10) · France (10) · Japan (10) · Czechia (9) · South Korea (9)
Top investigators Benjamin D Ehst, MD, PhD (1) · Elke de Jong, MD, PhD (1) · Jaehwan Kim, MD, PhD (1) · Jonathan Samuels, MD (1)
Results publications PMID 31054118 , PMID 31667790 , PMID 34921669 , PMID 36178584 , PMID 37368103 , PMID 39054592 , PMID 39131711 , PMID 39485390 , PMID 33052382 , PMID 35644154 , PMID 35839335 , PMID 35931879 , PMID 38739215 , PMID 39073712 , PMID 39120849 , PMID 39802486 , PMID 39909280 , PMID 41028616 , PMID 41318485 , PMID 29945918 , PMID 30097359 , PMID 32267471 , PMID 33512666 , PMID 34157132 , PMID 34656148 , PMID 34815219 , PMID 34911706 , PMID 35050485 , PMID 35644155 , PMID 35701011 , PMID 35801915 , PMID 36282530 , PMID 36282537 , PMID 36892753 , PMID 36917429 , PMID 37296268 , PMID 37488811 , PMID 37797293 , PMID 38498139 , PMID 38498141 , PMID 38863178 , PMID 39018531 , PMID 39037800 , PMID 39105965 , PMID 39208985 , PMID 39358667 , PMID 39516454 , PMID 39707077 , PMID 39804294 , PMID 39978685
NIH funding 2023 (6) , 2016 (5) , 2019 (4) , 2014 (3) , 2015 (3) , 2017 (2) , 2025 (1) , K23AR080043 (1)